TY - JOUR
T1 - Association of Pretreatment Physical and Geriatric Parameters with Treatment Tolerance and Survival in Elderly Patients with Stage I-II Non-Small Cell Lung Cancer
T2 - An Evaluation of Usual Care Data
AU - Voorn, Melissa J J
AU - Bootsma, Merle F R
AU - Bootsma, Gerben P
AU - van Kampen-van den Boogaart, Vivian E M
AU - van Riet, Geerten J A
AU - de Ruysscher, Dirk K
AU - Bongers, Bart C
AU - Janssen-Heijnen, Maryska L G
N1 - Funding Information:
This study was supported by an unconditional research grant (E.19.31.018-4) from the Research and Innovation Fund VieCuri (Fonds Wetenschap en Innovatie VieCuri, Venlo, the Netherlands). This research has not received any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.
Publisher Copyright:
© 2022 by the authors.
PY - 2022/12/5
Y1 - 2022/12/5
N2 - In this study, the association of pretreatment physical and geriatric parameters with treatment tolerance and survival in elderly patients with stage I-II NSCLC was evaluated. Retrospective data for patients aged ≥70 years, diagnosed between 2016 and 2020 with stage I-II NSCLC, and who underwent surgery or stereotactic ablative radiotherapy (SABR) in a large Dutch teaching hospital were retrieved from medical records. Associations of pretreatment physical and geriatric parameters with treatment tolerance and survival were analyzed. Of 160 patients, 49 of 104 (47%) patients who underwent surgery and 21 of 56 (38%) patients who received SABR did not tolerate treatment. In univariable analysis, World Health Organization (WHO) performance status ≥ 2, short nutritional assessment questionnaire score > 1, short physical performance battery score ≤ 9, and geriatric-8 score ≤ 14 were significantly associated with postoperative complications. Forced expiratory volume of one second < 80% of predicted was significantly associated with intolerance of SABR. In multivariable analysis, WHO performance status ≥ 2 and diffusing capacity for carbon monoxide < 80% were significantly associated with decreased overall survival. This is the first study that investigated the association between pretreatment physical and geriatric parameters and treatment outcomes in patients with stage I-II NSCLC. Evaluation of physical and geriatric parameters before treatment initiation seems highly recommended to select patients who might benefit from preventive interventions before and/or during treatment.
AB - In this study, the association of pretreatment physical and geriatric parameters with treatment tolerance and survival in elderly patients with stage I-II NSCLC was evaluated. Retrospective data for patients aged ≥70 years, diagnosed between 2016 and 2020 with stage I-II NSCLC, and who underwent surgery or stereotactic ablative radiotherapy (SABR) in a large Dutch teaching hospital were retrieved from medical records. Associations of pretreatment physical and geriatric parameters with treatment tolerance and survival were analyzed. Of 160 patients, 49 of 104 (47%) patients who underwent surgery and 21 of 56 (38%) patients who received SABR did not tolerate treatment. In univariable analysis, World Health Organization (WHO) performance status ≥ 2, short nutritional assessment questionnaire score > 1, short physical performance battery score ≤ 9, and geriatric-8 score ≤ 14 were significantly associated with postoperative complications. Forced expiratory volume of one second < 80% of predicted was significantly associated with intolerance of SABR. In multivariable analysis, WHO performance status ≥ 2 and diffusing capacity for carbon monoxide < 80% were significantly associated with decreased overall survival. This is the first study that investigated the association between pretreatment physical and geriatric parameters and treatment outcomes in patients with stage I-II NSCLC. Evaluation of physical and geriatric parameters before treatment initiation seems highly recommended to select patients who might benefit from preventive interventions before and/or during treatment.
U2 - 10.3390/cancers14235994
DO - 10.3390/cancers14235994
M3 - Article
C2 - 36497476
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 23
M1 - 5994
ER -